Current Report Filing (8-k)
April 01 2016 - 4:26PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 28, 2016
ONCOTHYREON INC.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-33882
|
|
26-0868560
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
2601 Fourth Avenue, Suite 500
Seattle, Washington 98121
(Address of principal executive offices, including zip code)
(206) 801-2100
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
Resignation of Chief Medical Officer
On March 28, 2016, Dr. Diana Hausman provided notice to Oncothyreon Inc. (the Company) of her decision to resign for
personal reasons as Chief Medical Officer, effective April 1, 2016 (the Separation Date). In connection with her resignation, the Board of Directors of the Company approved, and Dr. Hausman and the Company have entered into, a
Letter Agreement (the Letter Agreement), which is filed as Exhibit 10.1 to this 8-K. Pursuant to the Letter Agreement, Dr. Hausman will receive certain benefits upon resignation, including (i) payment of COBRA benefits through
May 31, 2016 and (ii) an extension of the exercise period for each of Dr. Hausmans outstanding, vested and exercisable stock options as of the Separation Date to 5:00 pm (Pacific Daylight Time) on June 30, 2016, which
additional benefits shall be conditioned on Dr. Hausmans entry into a release agreement, which is filed as Exhibit 10.2 to this 8-K.
Item 9.01
|
Financial Statements and Exhibits
|
(d) Exhibits.
|
|
|
Exhibit
Number
|
|
Description
|
|
|
10.1
|
|
Letter Agreement by and between Oncothyreon Inc. and Dr. Diana Hausman.
|
|
|
10.2
|
|
Release by and between Oncothyreon Inc. and Dr. Diana Hausman
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
ONCOTHYREON INC.
|
|
|
By:
|
|
/s/ Julia M. Eastland
|
|
|
Julia M. Eastland
|
|
|
Chief Financial Officer
|
Date: April 1, 2016
EXHIBIT INDEX
|
|
|
Exhibit
Number
|
|
Description
|
|
|
10.1
|
|
Letter Agreement by and between Oncothyreon Inc. and Dr. Diana Hausman.
|
|
|
10.2
|
|
Release by and between Oncothyreon Inc. and Dr. Diana Hausman
|
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Sep 2023 to Sep 2024